Clinical trials: in Kuwait
Urothelial Carcinoma, Non-Small Cell Lung Cancer
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This is a non-interventional, multi-country, multi-centre, multiple cohort prospective study, with retrospective collection of prior medical/treatment history data from medical records, designed to assess the real-world outcomes…
- Conditions
- Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- IMreal (NCT03782207)
- Testing
- Atezolizumab
- Where
- 257 sites in Argentina, Austria and 28 more
- Volunteers
- 2,756 people
- Sponsor
- Hoffmann-La Roche
Dermatitis Atopic
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
Primary Objective: To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant…
- Trial name
- GLOBOSTAD (NCT03992417)
- Testing
- Dupilumab SAR231893 (REGN668)
- Where
- 105 sites in Argentina, Australia and 20 more
- Volunteers
- 955 people
- Sponsor
- Sanofi
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease
Fibrosis Lessens After Metabolic Surgery
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis
- Trial name
- FLAMES (NCT06374875)
- Testing
- Metabolic surgery, Incretin-Based Therapy
- Where
- 22 sites in United States, Brazil and 11 more
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Plasma Cell Myeloma
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Primary Objective: To assess the effectiveness, in terms of overall response rate (ORR) of isatuximab patients with RRMM in routine clinical practice, within 12 months To assess other effectiveness parameters such as progression…
- Trial name
- IONA-MM (NCT04458831)
- Testing
- isatuximab SAR650984, Pomalidomide, Dexamethasone
- Where
- 129 sites in United States, Argentina and 19 more
- Volunteers
- 583 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Dapagliflozin Plus Pioglitazone in T1DM
Purpose: To examine the effect of addition of combination therapy with dapagliflozin plus pioglitazone to insulin on glucose control and plasma ketone concentration in patients with type 1 diabetes (T1DM) Research Design: 120…
- Trial name
- NCT03878459
- Testing
- Pioglitazone 45 mg
- Where
- 3 sites in United States, Israel and 1 more
- Volunteers
- 120 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Asthma
Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)
Primary Objective: The primary objective of the study is to characterize patients initiating DUPIXENT for asthma in a real-world setting, with respect to their medical history, including asthma history and asthma treatment…
- Trial name
- REVEAL (NCT04550962)
- Testing
- Dupilumab SAR231893
- Where
- 41 sites in Argentina, Chile and 10 more
- Volunteers
- 376 people
- Sponsor
- Sanofi
Hemophilia A
Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is used to treat people with Hemophilia A in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians…
- Trial name
- HEM-POWR (NCT03932201)
- Testing
- Damoctocog alfa pegol (Jivi, Bay94-9027)
- Where
- 29 sites in United States, Belgium and 18 more
- Volunteers
- 371 people
- Sponsor
- Bayer
Glycogen Storage Disease Type II, Pompe Disease
Pompe Disease Registry Protocol
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both…
- Trial name
- NCT00231400
- Where
- 272 sites in United States, Argentina and 42 more
- Volunteers
- 2,000 people
- Sponsor
- Genzyme, a Sanofi Company
Patient-Ventilator Interaction, Asynchrony, Patient-Ventilator
Standardising Terminology, Classification, Diagnostic Recognition and Reporting of Patient-ventilator Interactions: Protocol for an International Delphi Consensus Study
Patient-ventilator interaction describes how a mechanically ventilated patient's breathing effort aligns with ventilator support.
- Trial name
- INTERACT (NCT07638540)
- Testing
- Modified Delphi consensus survey
- Where
- Kuwait
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Al Adan Hospital Kuwait
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN.
- Trial name
- NCT05430971
- Where
- 22 sites in United States, Armenia and 13 more
- Volunteers
- 200 people
- Sponsor
- Immune Oncology Research Institute
Root Canal Infection, Periapical Diseases
Calcium Silicate Sealer-based Obturation in Root Canal Retreatment
This study will evaluate the outcome of calcium silicate sealer-based obturations in root canal retreatment.
- Trial name
- NCT05714384
- Testing
- CeraSeal (Calcium Silicate-based Root Canal Sealer)
- Where
- Kuwait
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Ministry of Health, Kuwait
Relapsing-Remitting Multiple Sclerosis
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
The main objectives of Part 1 are as follows: To evaluate the safety, tolerability, and efficacy of BG00012 in pediatric participants with RRMS, as compared with a disease-modifying treatment and to assess health outcomes and…
- Trial name
- CONNECT (NCT02283853)
- Testing
- dimethyl fumarate, Interferon β-1a
- Where
- 62 sites in United States, Belgium and 16 more
- Volunteers
- 156 people
- Sponsor
- Biogen
Cardiac Arrhythmias, Symptoms and Signs
Confirm Rx Insertable Cardiac Monitor SMART Registry
The purpose of the Confirm Rx SMART Registry is to collect real world data to assess the safety and performance of the Confirm Rx Insertable Cardiac Monitor (ICM) and system over a 12 month period.
- Conditions
- Cardiac Arrhythmias, Symptoms and Signs, Atrial Fibrillation
- Trial name
- NCT03505801
- Testing
- Confirm Rx ICM insertion procedure
- Where
- 113 sites in United States, Algeria and 22 more
- Volunteers
- 1,826 people
- Sponsor
- Abbott Medical Devices
Obesity
LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy
The aim of the current study is to determine whether resistance exercise and/or protein intake can preserve lean mass and improve physical function in patients with obesity initiating semaglutide/tirzepatide therapy.
- Trial name
- LEAN-PREP (NCT06885736)
- Testing
- Resistance exercise, Protein Intake
- Where
- Kuwait
- Volunteers
- 232 people
- Sponsor
- Dasman Diabetes Institute
Type1diabetes, Obesity
Tirzepatide Use in People With Obesity and Type 1 Diabetes
Tirzepatide, a gut hormone-based medication, has shown promising results in treating obesity, with ~22% weight loss and mild side effects.
- Trial name
- NCT07096908
- Testing
- Tirzepatide
- Where
- Kuwait
- Volunteers
- 60 people
- Sponsor
- Dasman Diabetes Institute
Bariatric Surgery Candidate, Type2 Diabetes
Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery
This study evaluates the effect of SGLT-2 inhibitors (dapagliflozin) on the blood glucose excursions by a continuous glucose monitoring system, the incidence of hypoglycemia and hyperglycemia and change in glycated hemoglobin…
- Trial name
- NCT07515391
- Testing
- Dapagliflozin 10 MG
- Where
- Kuwait
- Volunteers
- 30 people
- Sponsor
- Dasman Diabetes Institute
Axial Spondylarthritis (axSpA)
A Study of the Change in Early and Sustained Pain Control in Axial Spondylarthritis in Adult Participants Receiving Upadacitinib
Axial spondyloarthritis (axSpA) is an immune-mediated inflammatory disease primarily affecting the axial skeleton. The most frequent axSpA symptom is chronic, often inflammatory back pain (IBP) that might be difficult to…
- Trial name
- UPSTAND (NCT04846244)
- Where
- 160 sites in Argentina, Australia and 14 more
- Volunteers
- 708 people
- Sponsor
- AbbVie
Severe Asthma
Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients
This study aims to generate real-world data on the characteristics of patients receiving benralizumab to assess early PRO parameters as well as long-term treatment effects in the Gulf cooperative council (Kingdom of Saudi Arabia…
- Trial name
- iOUTRUN (NCT05603845)
- Where
- 24 sites in Colombia, Dominican Republic and 6 more
- Volunteers
- 291 people
- Sponsor
- AstraZeneca
Mucopolysaccharidosis I (MPS I)
Mucopolysaccharidosis I (MPS I) Registry
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I.
- Trial name
- NCT00144794
- Where
- 141 sites in United States, Argentina and 35 more
- Volunteers
- 1,406 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis
Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
This is a multicentre non-interventional study aimed at evaluating the real-world effectiveness and safety of ocrelizumab treatment in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis…
- Trial name
- MuSicalE (NCT03593590)
- Testing
- Ocrelizumab
- Where
- 158 sites in Austria, Belgium and 23 more
- Volunteers
- 1,710 people
- Sponsor
- Hoffmann-La Roche